[107 Pages Report] The global viral vector manufacturing market was valued at USD 273.2 million in 2017 and is expected to grow at a CAGR of 20.0% during the forecast period to reach to USD 815.8 million by 2023. The base year considered for the study is 2017 and the forecast for the market size is provided for the period between 2018 and 2023.

Objectives of the Study

To define, describe, and forecast the global viral vector manufacturing market by type, disease, application, end user, and region

To provide detailed information about the major factors influencing market growth (drivers, restraints, opportunities, and challenges)

To strategically analyze micromarkets with respect to individual growth trends, prospects, and contributions to the overall market

To analyze market opportunities for stakeholders and provide details of the competitive landscape for key players

To forecast the size of market segments with respect to five main regions, namely, North America, Europe, Asia Pacific, and Rest of the World (RoW)

To profile key players and comprehensively analyze their core competencies in terms of key market developments, product portfolios, and financials

To track and analyze competitive developments such as product launches, collaborations, partnerships and agreements, acquisitions, expansions, and other developments in the market

Research Methodology

Top-down and bottom-up approaches were used to validate the size of the viral vector manufacturing market and estimate the size of other dependent submarkets. Various secondary sources such as Source: Annual Reports, SEC Filings, Investor Presentations, World Health Organization (WHO), National Institutes of Health (NIH), US Food and Drug Administration (FDA), American Society of Gene & Cell Therapy (ASGCT), European Medicines Agency (EMA), European Society for Gene and Cell Therapy (ESGCT), World Bank, Academic Journals, Company Websites, Expert Interviews, Annual Reports, SEC Filings, Investor Presentations, and MarketsandMarkets Analysis have been used to identify and collect information useful for the study of this market. Primary sources such as experts from both supply and demand sides have been interviewed to obtain and validate information as well as to assess the dynamics of this market. The breakdown of profiles of primaries is shown in the figure below:

Geographical Analysis

Company Information

The global viral vector manufacturing market is projected to reach USD 815.8 million by 2023 from USD 327.8 million in 2018, at a CAGR of 20.0%. Some key factors driving market growth include the rising prevalence of target diseases and disorders, the availability of funding for gene therapy development, effectiveness of viral vectors in gene therapy delivery, and ongoing research into viral vector-based gene & cell therapies. Untapped potential in emerging markets is expected to offer lucrative growth opportunities for players in the market.

In this report, the global market is segmented by type, disease, application, end user. By type, the market is segmented into retroviral vectors, adenoviral vectors, adeno-associated viral vectors, and other viral vectors. The adeno-associated viral vector manufacturing segment is expected to grow at the highest CAGR during the forecast period as they have applications in most cell-based gene therapies.

Based on disease, the market is segmented into cancer, genetic disorders, infectious diseases, and other diseases. In 2018, cancer is expected to account for the largest share of the global market. Its large share can be attributed to growing research on viral vector gene therapies for cancer.

By application, the viral vector manufacturing market is segmented into gene therapy and vaccinology. The gene therapy segment is expected to grow at the highest rate during the forecast period. The availability of effective viral vector gene therapies for rare diseases and cancers, ongoing research activities on viral vector gene therapies, and the recent approval of several viral vector gene therapies are driving the growth of this market.

Based on end users, the viral vector manufacturing market is segmented into pharmaceutical and biopharmaceutical companies and research institutes. In 2018, pharmaceutical and biopharmaceutical companies are expected to account for the largest share of the global market. The successful launch of viral vector gene therapies and a robust pipeline of such therapies are the key factors contributing to the growth of the pharmaceutical and biopharmaceutical companies segment during the forecast period.

Geographically, Asia Pacific is expected to grow at the fastest rate viral vector manufacturing market during the forecast period. The fast growth of this regional segment can be attributed to the growing research activities to launch novel gene therapies in the untapped markets of this region.

While the overall market is expected to grow during the forecast period, the high price of gene therapies and short shelf-life of viral vectors are likely to restrain the growth of this market to a certain extent. The major players in the global market include Lonza (Switzerland), Merck (Germany), Oxford BioMedica (UK), CGT Catapult (UK), Cobra Biologics (UK), uniQure (Netherlands), FUJIFILM Diosynth Biotechnologies (US), and Spark Therapeutics (US).

To speak to our analyst for a discussion on the above findings, click Speak to Analyst